Chest, Vol 85, 34-38, Copyright © 1984 by American College of Chest Physicians

ARTICLES

Assessment of tachyphylaxis following prolonged therapy of asthma with inhaled albuterol aerosol

LH Repsher, JA Anderson, RK Bush, CJ Falliers, I Kass, JP Kemp, C Reed, S Siegel and DR Webb

Controversy exists concerning possible tachyphylaxis of the acute bronchodilating effect of albuterol, especially with regard to the duration of its acute bronchodilating action. We evaluated 140 patients with bronchial asthma in a prospective double-blind controlled study of possible tachyphylaxis to albuterol aerosol as compared to isoproterenol aerosol. We demonstrated statistically significant tachyphylaxis with regard to duration of acute bronchodilating effect. We believe that this tachyphylaxis is not clinically significant because there was no tachyphylaxis with regard to peak bronchodilating effect and because the duration of bronchodilating effect remains significantly greater, both quantitatively and statistically, when compared to isoproterenol aerosol. Moreover, it appeared that most of the tachyphylaxis was present at four weeks of therapy. There was a small increment of tachyphylaxis after eight weeks of therapy, but no further increase in tachyphylaxis was demonstrated after 13 weeks of inhaled albuterol therapy. We therefore feel that clinically significant tachyphylaxis to inhaled albuterol aerosol must be quite unusual and that chronic therapy with inhaled albuterol aerosol is probably both safe and efficacious for bronchospastic disorders.

This article has been cited by other articles:

				T. NIU, J. J. ROGUS, C. CHEN, B. WANG, J. YANG, Z. FANG, S. T. WEISS, and X. XU Familial Aggregation of Bronchodilator Response . A Community-Based Study Am. J. Respir. Crit. Care Med., November 1, 2000; 162(5): 1833 - 1837. [Abstract] [Full Text]

				J. W. Ramsdell, N. M. Klinger, B. P. Ekholm, and G. L. Colice Safety of Long-term Treatment With HFA Albuterol Chest, April 1, 1999; 115(4): 945 - 951. [Abstract] [Full Text] [PDF]

				H. Nelson, J. P. Kemp, S. Bieler, L. M. Vaughan, and M. R. Hill Comparative Efficacy and Safety of Albuterol Sulfate Spiros Inhaler and Albuterol Metered-Dose Inhaler in Asthma Chest, February 1, 1999; 115(2): 329 - 335. [Abstract] [Full Text] [PDF]

				J. A. Nelson, L. Strauss, M. Skowronski, R. Ciufo, R. Novak, and E.R. McFadden Effect of Long-Term Salmeterol Treatment on Exercise-Induced Asthma N. Engl. J. Med., July 16, 1998; 339(3): 141 - 146. [Abstract] [Full Text] [PDF]

				D. E. Wachsman, J. P. Kavaler, I. P. Sugár, E. N. Schachter, W. Gonsiorek, and S. Maayani Kinetic Studies of Desensitization and Resensitization of the Relaxation Response to Beta-2 Adrenoceptor Agonists in Isolated Guinea Pig Trachea J. Pharmacol. Exp. Ther., January 1, 1997; 280(1): 332 - 345. [Abstract] [Full Text]

				J. M. Drazen, E. Israel, H. A. Boushey, V. M. Chinchilli, J. V. Fahy, J. E. Fish, S. C. Lazarus, R. F. Lemanske, R. J. Martin, S. P. Peters, et al. Comparison of Regularly Scheduled with As-Needed Use of Albuterol in Mild Asthma N. Engl. J. Med., September 19, 1996; 335(12): 841 - 847. [Abstract] [Full Text] [PDF]

				H. S. Nelson {beta}-Adrenergic Bronchodilators N. Engl. J. Med., August 24, 1995; 333(8): 499 - 507. [Full Text] [PDF]